PCM
ZBIO

Prelude Capital Management’s Zenas BioPharma ZBIO Stock Holding History

Prelude Capital Management’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$325K Buy
+16,645
New +$374K 0.02% 679

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

Prelude Capital Management's ZBIO Position: Q1 2026 in Review

Prelude Capital Management opened a new position in Zenas BioPharma (ZBIO) in Q1 2026: 16,645 shares worth $325K. The stake represents 0.02% of the portfolio and ranks #679 among its holdings.

139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • Prelude Capital Management held 16,645 shares of Zenas BioPharma worth $325K as of Q1 2026.
  • Zenas BioPharma was a new Prelude Capital Management position in Q1 2026.
  • Zenas BioPharma made up 0.02% of Prelude Capital Management's portfolio in Q1 2026, its #679 holding.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.